IFN-α/β/IFN-γ/IL-15 pathways were associated with improved survival and response in patients treated with ICIs, and GBP1 could serve as a surrogate to IFN-α/β/IFN-γ/IL-15 activity in pan-cancer scale analysis. This evidence concerns the gene GBP1 and cancer.